Anticoagulation therapy, Isocitrate Dehydrogenase 1 (IDH1) mutations, O6-Methylguanine-DNA Methyltransferase (MGMT) methylation, radiotherapy, chemotherapy, and prolonged bed rest were protective against VTE, while increased tumor volume, Grade 4 glioma, Epidermal Growth Factor Receptor (EGFR) positivity, p53 mutations, glucocorticoid therapy and central venous catheter placement (CVCP) placement promoted VTE risk. This evidence concerns the gene IDH1 and central nervous system cancer.